Detail page

Knowledge Web

Person

Lukas Bunse (1988-)

Arzt

Name	Lukas Bunse
Time	1988- (Date of birth and death)
Place	Heidelberg (Wirkungsort) Villingen-Schwenningen (Geburtsort) Deutschland
Gender	männlich
Academic degree	Dr. med. (Univ. Heidelberg) (2016) Dr. rer. nat. (an der Naturwissenschaftlich-Mathematischen Gesamtfakultät der Ruprecht-Karls-Universität Heidelberg) (2020)
Profession	Arzt (characteristic profession)
Related	Neurologische Universitätsklinik (Heidelberg) (09/2016-07/2019) Neurologische Klinik (Mannheim) (seit 01/2019) Klinikum Heidelberg Biowissenschaften (Studienfach)
Further information	Klinische Kooperationseinheit Neuroimmunologie und Hirntumorimmunologie, Neurologische Klinik, Universitätsklinikum Heidelberg; 01.09.2019-31.12.2024: Assistenzarzt in der Neurologischen Klinik der Medizinischen Fakultät Mannheim der Universität Heidelberg
Record type	Person
GND-Identifier	1051941229
Record ID	1051941229
Involved in show all Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy A H3K27M-targeted vaccine in adults with diffuse midline glioma Dysfunctional dendritic cells limit antigen-specific T cell response in glioma The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients Clinical and Translational Advances in Glioma Immunotherapy AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas Intrathecal activation of CD8 + memory T cells in IgG4‐related disease of the brain parenchyma Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas Phenotype and modulation of T cell responses in isocitrate dehydrogenase 1 mutant gliomas Actively personalized vaccination trial for newly diagnosed glioblastoma Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate Vaccine Strategies in Gliomas Immuntherapien bei Gliomen Spontane Immunantworten gegen mutierte Isozitratdehydrogenase 1 in Gliompatienten

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Lukas Bunse (1988-)

Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy

A H3K27M-targeted vaccine in adults with diffuse midline glioma

Dysfunctional dendritic cells limit antigen-specific T cell response in glioma

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

Clinical and Translational Advances in Glioma Immunotherapy

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

Intrathecal activation of CD8 + memory T cells in IgG4‐related disease of the brain parenchyma

Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas

Phenotype and modulation of T cell responses in isocitrate dehydrogenase 1 mutant gliomas

Actively personalized vaccination trial for newly diagnosed glioblastoma

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

Vaccine Strategies in Gliomas

Immuntherapien bei Gliomen

Spontane Immunantworten gegen mutierte Isozitratdehydrogenase 1 in Gliompatienten